Brainsway (NASDAQ:BWAY) Releases Earnings Results, Beats Estimates By $0.07 EPS

Brainsway (NASDAQ:BWAY) released its quarterly earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.07, Zacks reports. The business had revenue of $15.53 million during the quarter, compared to analysts’ expectations of $14.63 million. Brainsway had a return on equity of 12.51% and a net margin of 15.68%.

Here are the key takeaways from Brainsway’s conference call:

• BrainsWay delivered strong Q1 2026 results, with revenue up 35% year over year to $15.5 million, net income more than doubling to $2.3 million, and adjusted EBITDA rising 119% to $2.8 million.
• The company reported its 11th consecutive quarter of profitability, supported by expanding margins, disciplined cost control, and a recurring revenue model that continues to gain traction.
• Demand indicators improved, including 117 Deep TMS systems shipped in the quarter, a total install base of about 1,820 systems, and remaining performance obligations rising to $75 million, with most new contracts being multi-year agreements.
• Management highlighted reimbursement and adoption progress for both Deep TMS and the SWIFT protocol, including expanded payer coverage, growing interest from providers, and expectations for $40 million-$50 million of SWIFT-covered lives by year-end.
• The company remains focused on pipeline and strategic expansion, including an upcoming FDA filing for PTSD symptoms in MDD, ongoing alcohol use disorder trials, and additional minority investments in mental health networks and Neurolief’s ProlivRx platform.

Brainsway Stock Down 7.9%

Shares of Brainsway stock traded down $1.29 during trading on Friday, reaching $15.03. The company’s stock had a trading volume of 260,654 shares, compared to its average volume of 191,947. The company has a market cap of $601.80 million, a price-to-earnings ratio of 42.94 and a beta of 1.23. Brainsway has a 1-year low of $4.94 and a 1-year high of $17.35. The company has a 50-day simple moving average of $14.52 and a two-hundred day simple moving average of $11.62.

Institutional Trading of Brainsway

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its holdings in shares of Brainsway by 2.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock valued at $490,000 after buying an additional 589 shares during the period. Man Group plc lifted its holdings in shares of Brainsway by 4.5% in the 4th quarter. Man Group plc now owns 18,027 shares of the company’s stock valued at $343,000 after buying an additional 782 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Brainsway by 7.4% in the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock valued at $431,000 after buying an additional 1,964 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Brainsway in the 2nd quarter valued at about $85,000. Finally, Bank of America Corp DE acquired a new position in shares of Brainsway in the 3rd quarter valued at about $107,000. Institutional investors and hedge funds own 30.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright lowered their price objective on Brainsway from $30.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, March 12th. Northland Securities set a $15.00 price objective on Brainsway in a research note on Thursday, January 22nd. Zacks Research lowered Brainsway from a “strong-buy” rating to a “hold” rating in a research note on Monday. Wall Street Zen raised Brainsway from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings raised Brainsway from a “hold (c)” rating to a “buy (b-)” rating in a research note on Friday, April 24th. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.00.

About Brainsway

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.